Recent Developments:
In February 2021, Roche announced detailed results from phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema and neovascular or wet age-related macular degeneration (nAMD).
In February 2020, Novartis received a European Commission approval for marketing of Beovu. It is an anti-VEGF agent used for treating wet-AMD patients.
Macular Degeneration Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients